期刊
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
卷 8, 期 5, 页码 555-564出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERI.10.28
关键词
Clostridium difficile; fidaxomicin; nitazoxanide; rifaximin; treatment update
资金
- Salix Pharmaceuticals
- Romark Institute for Medical Research
- Optimer Pharmaceuticals
- Viropharma, Inc.
- National Institute of Diabetes and Digestive and Kidney Diseases [1K23DK084513-01]
- IOMAI Corporation
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK084513] Funding Source: NIH RePORTER
Clostridium difficile infection (CDI) is the most common cause of identifiable diarrhea in hospitalized patients. The incidence and severity of CDIs are increasing. The increased incidence and severity of the disease has sparked interest in the optimal treatment of CDI as well as the use of new therapies and drug discovery. Current treatment strategies are inadequate with decreased response rates to metronidazole, and high recurrence rates with the use of metronidazole and oral vancomycin. Although incidence rates continue to be low, in vitro resistance to antibiotics used for the treatment of CDI has been noted. Recently, important data has emerged on new anti-C. difficile antibiotics such as rifaximin, rifalazil, fidaxomicin, nitazoxanide, tigecycline and ramoplanin. The purpose of this review is to provide an update on the in vitro susceptibility and new antibiotic treatment options for CDI. This review will focus primarily on scientific studies published in the last 36 months in order to provide an up-to-date review on the topic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据